S&P 500   4,298.86 (+0.11%)
DOW   33,876.78 (+0.13%)
QQQ   354.50 (+0.38%)
AAPL   180.96 (+0.22%)
MSFT   326.79 (+0.47%)
META   264.95 (+0.14%)
GOOGL   122.23 (+0.07%)
AMZN   123.43 (-0.66%)
TSLA   244.40 (+4.06%)
NVDA   387.70 (+0.68%)
NIO   7.74 (-0.64%)
BABA   85.50 (-0.74%)
AMD   124.92 (+3.20%)
T   15.96 (-0.75%)
F   13.74 (+1.18%)
MU   65.43 (+0.17%)
CGC   0.68 (-1.45%)
GE   106.30 (+0.22%)
DIS   91.95 (-0.63%)
AMC   4.77 (+1.92%)
PFE   38.97 (-0.31%)
PYPL   63.49 (-1.17%)
NFLX   420.02 (+2.60%)
S&P 500   4,298.86 (+0.11%)
DOW   33,876.78 (+0.13%)
QQQ   354.50 (+0.38%)
AAPL   180.96 (+0.22%)
MSFT   326.79 (+0.47%)
META   264.95 (+0.14%)
GOOGL   122.23 (+0.07%)
AMZN   123.43 (-0.66%)
TSLA   244.40 (+4.06%)
NVDA   387.70 (+0.68%)
NIO   7.74 (-0.64%)
BABA   85.50 (-0.74%)
AMD   124.92 (+3.20%)
T   15.96 (-0.75%)
F   13.74 (+1.18%)
MU   65.43 (+0.17%)
CGC   0.68 (-1.45%)
GE   106.30 (+0.22%)
DIS   91.95 (-0.63%)
AMC   4.77 (+1.92%)
PFE   38.97 (-0.31%)
PYPL   63.49 (-1.17%)
NFLX   420.02 (+2.60%)
S&P 500   4,298.86 (+0.11%)
DOW   33,876.78 (+0.13%)
QQQ   354.50 (+0.38%)
AAPL   180.96 (+0.22%)
MSFT   326.79 (+0.47%)
META   264.95 (+0.14%)
GOOGL   122.23 (+0.07%)
AMZN   123.43 (-0.66%)
TSLA   244.40 (+4.06%)
NVDA   387.70 (+0.68%)
NIO   7.74 (-0.64%)
BABA   85.50 (-0.74%)
AMD   124.92 (+3.20%)
T   15.96 (-0.75%)
F   13.74 (+1.18%)
MU   65.43 (+0.17%)
CGC   0.68 (-1.45%)
GE   106.30 (+0.22%)
DIS   91.95 (-0.63%)
AMC   4.77 (+1.92%)
PFE   38.97 (-0.31%)
PYPL   63.49 (-1.17%)
NFLX   420.02 (+2.60%)
S&P 500   4,298.86 (+0.11%)
DOW   33,876.78 (+0.13%)
QQQ   354.50 (+0.38%)
AAPL   180.96 (+0.22%)
MSFT   326.79 (+0.47%)
META   264.95 (+0.14%)
GOOGL   122.23 (+0.07%)
AMZN   123.43 (-0.66%)
TSLA   244.40 (+4.06%)
NVDA   387.70 (+0.68%)
NIO   7.74 (-0.64%)
BABA   85.50 (-0.74%)
AMD   124.92 (+3.20%)
T   15.96 (-0.75%)
F   13.74 (+1.18%)
MU   65.43 (+0.17%)
CGC   0.68 (-1.45%)
GE   106.30 (+0.22%)
DIS   91.95 (-0.63%)
AMC   4.77 (+1.92%)
PFE   38.97 (-0.31%)
PYPL   63.49 (-1.17%)
NFLX   420.02 (+2.60%)
NASDAQ:DMAC

DiaMedica Therapeutics (DMAC) Competitors

$3.14
-0.09 (-2.79%)
(As of 06/9/2023 ET)
Compare
Today's Range
$3.14
$3.45
50-Day Range
$1.53
$3.23
52-Week Range
$1.12
$3.48
Volume
119,067 shs
Average Volume
48,745 shs
Market Capitalization
$83.09 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$10.00

DMAC vs. CLNN, IPA, APLT, VLON, BLPH, IMUX, HOOK, RZLT, FBIO, and SYRS

Should you be buying DiaMedica Therapeutics stock or one of its competitors? The main competitors of DiaMedica Therapeutics include Clene (CLNN), ImmunoPrecise Antibodies (IPA), Applied Therapeutics (APLT), Vallon Pharmaceuticals (VLON), Bellerophon Therapeutics (BLPH), Immunic (IMUX), Hookipa Pharma (HOOK), Rezolute (RZLT), Fortress Biotech (FBIO), and Syros Pharmaceuticals (SYRS). These companies are all part of the "pharmaceutical preparations" industry.

DiaMedica Therapeutics vs.

Clene (NASDAQ:CLNN) and DiaMedica Therapeutics (NASDAQ:DMAC) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, community ranking, media sentiment, analyst recommendations, dividends, profitability, valuation, risk and earnings.

DiaMedica Therapeutics has lower revenue, but higher earnings than Clene. DiaMedica Therapeutics is trading at a lower price-to-earnings ratio than Clene, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Clene$470 thousand171.79-$29.92 million-$0.39-2.64
DiaMedica TherapeuticsN/AN/A-$13.68 million-$0.59-5.32

DiaMedica Therapeutics received 39 more outperform votes than Clene when rated by MarketBeat users. However, 73.44% of users gave Clene an outperform vote while only 60.99% of users gave DiaMedica Therapeutics an outperform vote.

CompanyUnderperformOutperform
CleneOutperform Votes
47
73.44%
Underperform Votes
17
26.56%
DiaMedica TherapeuticsOutperform Votes
86
60.99%
Underperform Votes
55
39.01%

5.9% of Clene shares are owned by institutional investors. Comparatively, 28.1% of DiaMedica Therapeutics shares are owned by institutional investors. 26.6% of Clene shares are owned by insiders. Comparatively, 6.5% of DiaMedica Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Clene has a beta of 0.37, meaning that its stock price is 63% less volatile than the S&P 500. Comparatively, DiaMedica Therapeutics has a beta of 1.72, meaning that its stock price is 72% more volatile than the S&P 500.

In the previous week, Clene had 1 more articles in the media than DiaMedica Therapeutics. MarketBeat recorded 2 mentions for Clene and 1 mentions for DiaMedica Therapeutics. Clene's average media sentiment score of 0.94 beat DiaMedica Therapeutics' score of 0.00 indicating that Clene is being referred to more favorably in the media.

Company Overall Sentiment
Clene Positive
DiaMedica Therapeutics Neutral

DiaMedica Therapeutics has a net margin of 0.00% compared to Clene's net margin of -5,151.64%. DiaMedica Therapeutics' return on equity of -46.58% beat Clene's return on equity.

Company Net Margins Return on Equity Return on Assets
Clene -5,151.64% -4,043.36% -112.21%
DiaMedica Therapeutics N/A -46.58% -43.51%

Clene currently has a consensus target price of $10.33, indicating a potential upside of 903.24%. DiaMedica Therapeutics has a consensus target price of $10.00, indicating a potential upside of 218.47%. Given Clene's stronger consensus rating and higher possible upside, research analysts plainly believe Clene is more favorable than DiaMedica Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Clene
0 Sell rating(s)
1 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
2.83
DiaMedica Therapeutics
0 Sell rating(s)
1 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.67

Summary

Clene beats DiaMedica Therapeutics on 10 of the 17 factors compared between the two stocks.


New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding DMAC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

DMAC vs. The Competition

MetricDiaMedica TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$83.09M$5.95B$4.59B$6.29B
Dividend YieldN/A2.59%2.27%6.19%
P/E Ratio-5.325.8096.5913.14
Price / SalesN/A333.413,289.3488.76
Price / CashN/A20.9592.19113.59
Price / Book2.624.774.695.30
Net Income-$13.68M$194.45M$118.07M$193.23M
7 Day Performance20.77%0.41%0.86%1.51%
1 Month Performance82.56%0.88%1.50%5.17%
1 Year Performance26.10%17.83%8.60%3.11%

DiaMedica Therapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
CLNN
Clene
1.9903 of 5 stars
$0.95
+1.1%
$10.00
+953.9%
-68.8%$74.38M$470,000.00-2.4395
IPA
ImmunoPrecise Antibodies
1.7006 of 5 stars
$3.02
+9.0%
$8.00
+165.3%
-39.2%$75.17M$15.32M-3.5973Positive News
APLT
Applied Therapeutics
2.1923 of 5 stars
$1.30
flat
$3.63
+178.8%
+15.7%$75.20M$10.66M-0.7634Positive News
VLON
Vallon Pharmaceuticals
0 of 5 stars
$5.59
-3.5%
N/A-60.8%$75.36M$100,000.00-7.173
BLPH
Bellerophon Therapeutics
2.2445 of 5 stars
$7.06
-5.1%
$30.00
+324.9%
-22.5%$73.78MN/A-5.7921Analyst Report
Insider Selling
Analyst Revision
News Coverage
Positive News
IMUX
Immunic
2.3691 of 5 stars
$1.74
+1.8%
$17.75
+920.1%
-55.0%$75.93MN/A-0.4855Positive News
HOOK
Hookipa Pharma
2.0116 of 5 stars
$1.39
+13.9%
$5.50
+295.7%
-41.2%$76.06M$15.98M-1.5156Gap Down
RZLT
Rezolute
1.9961 of 5 stars
$2.09
-0.5%
$11.80
+464.6%
-23.8%$76.97MN/A-1.8726Positive News
FBIO
Fortress Biotech
2.1671 of 5 stars
$0.54
-1.8%
$5.50
+924.2%
-44.8%$72.13M$75.74M-0.54173
SYRS
Syros Pharmaceuticals
2.4096 of 5 stars
$3.75
+1.4%
$15.75
+320.0%
-67.7%$77.25M$14.88M-0.39124Positive News

Related Companies and Tools

This page (NASDAQ:DMAC) was last updated on 6/9/2023 by MarketBeat.com Staff

My Account -